Patents by Inventor Daisuke Taniyama

Daisuke Taniyama has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9975906
    Abstract: The present invention provides the following compound having anti-HIV activity of formula: wherein, A1 is C, CR1A or N; A2 is C, CR2A, or N; A3 is CR3A, CR3AR3B, N, NR3C, O, S, SO, or SO2; A4 is CR4A, CR4AR4B, N, NR4C, O, S, SO, or SO2; A5 is C, CR5A, or N; T1 ring is substituted or unsubstituted monocyclic carbocycle or substituted or unsubstituted monocyclic heterocycle; R1 is halogen, cyano, nitro or —X1—R11; R2 is substituted or unsubstituted alkyl and the like; n is 1 or 2; R3 is hydrogen, substituted or unsubstituted aromatic carbocyclyl; R4 is hydrogen or a carboxy protecting group; the other symbols are as specified in the description.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: May 22, 2018
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Takashi Kawasuji, Daisuke Taniyama, Shuichi Sugiyama, Yoshinori Tamura
  • Patent number: 9725442
    Abstract: The present invention is related to a compound represented by formula (I), wherein X1, X2, X3, X4, X5, R5, R6, R7, R8, n, p, q, ring A and ring B are as described in the specification, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 24, 2012
    Date of Patent: August 8, 2017
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Kayoko Hata, Manami Masuda, Hiromi Nakai, Daisuke Taniyama, Hiroyuki Tobinaga, Yoshio Hato, Motohiro Fujiu
  • Publication number: 20170107234
    Abstract: The present invention provides the following compound having anti-HIV activity of formula: wherein, A1 is C, CR1A or N; A2 is C, CR2A, or N; A3 is CR3A, CR3AR3B, N, NR3C, O, S, SO, or SO2; A4 is CR4A, CR4AR4B, N, NR4C, O, S, SO, or SO2; A5 is C, CR5A, or N; T1 ring is substituted or unsubstituted monocyclic carbocycle or substituted or unsubstituted monocyclic heterocycle; R1 is halogen, cyano, nitro or —X1—R11; R2 is substituted or unsubstituted alkyl and the like; n is 1 or 2; R3 is hydrogen, substituted or unsubstituted aromatic carbocyclyl; R4 is hydrogen or a carboxy protecting group; the other symbols are as specified in the description.
    Type: Application
    Filed: May 15, 2015
    Publication date: April 20, 2017
    Applicant: Shionogi & Co., Ltd.
    Inventors: Takashi KAWASUJI, Daisuke TANIYAMA, Shuichi SUGIYAMA, Yoshinori TAMURA
  • Patent number: 9115029
    Abstract: An object of the invention is to provide, in porous thermal insulating firebricks formed by molding and drying bubble-containing slurry obtained by foaming slurry containing a fire resistant powder and water, a thermal insulating firebrick superior in thermal insulating property in spite of the same composition and porosity. A porous thermal insulating firebrick formed by molding and drying bubble-containing slurry obtained by foaming slurry containing a fire resistant powder with a heat resistant temperature of 1,000° C. or higher and water has the porosity of 60% or more, and 80% or more volume with respect to a total pore volume of the inside of the thermal insulating firebrick consists of pores having a pore size of 200 ?m or less.
    Type: Grant
    Filed: June 4, 2012
    Date of Patent: August 25, 2015
    Assignee: HINOMARU YOGYO CO., LTD.
    Inventors: Daisuke Taniyama, Yasunari Nagasaki, Akira Terasawa
  • Publication number: 20140275074
    Abstract: The present invention is related to a compound represented by formula (I), wherein X1, X2, X3, X4, X5, R5, R6, R7, R8, n, p, q, ring A and ring B are as described in the specification, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 24, 2012
    Publication date: September 18, 2014
    Inventors: Kayoko Hata, Manami Masuda, Hiromi Nakai, Daisuke Taniyama, Hiroyuki Tobinaga, Yoshio Hato, Motohiro Fujiu
  • Publication number: 20140128242
    Abstract: An object of the invention is to provide, in porous thermal insulating firebricks formed by molding and drying bubble-containing slurry obtained by foaming slurry containing a fire resistant powder and water, a thermal insulating firebrick superior in thermal insulating property in spite of the same composition and porosity. A porous thermal insulating firebrick formed by molding and drying bubble-containing slurry obtained by foaming slurry containing a fire resistant powder with a heat resistant temperature of 1,000° C. or higher and water has the porosity of 60% or more, and 80% or more volume with respect to a total pore volume of the inside of the thermal insulating firebrick consists of pores having a pore size of 200 ?m or less.
    Type: Application
    Filed: June 4, 2012
    Publication date: May 8, 2014
    Applicant: HINOMARU YOGYO CO., LTD.
    Inventors: Daisuke Taniyama, Yasunari Nagasaki, Akira Terasawa
  • Publication number: 20120071475
    Abstract: Provided is a compound or a pharmaceutically acceptable salt thereof which inhibits the activity of PI3K to regulate many biological processes including the growth, differentiation, survival, proliferation, migration, metabolism, and the like of cells and is therefore useful for the prophylaxis/therapy of diseases including inflammatory diseases, arteriosclerosis, vascular/circulatory diseases, cancer/tumors, immune system diseases, cell proliferative diseases, infectious diseases, and the like. The above problem was solved by providing a urea derivative shown in the present specification, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 26, 2010
    Publication date: March 22, 2012
    Applicant: SHIONOGI & CO., LTD.
    Inventors: Daisuke Taniyama, Yasunori Mitsuoka, Kayoko Hata
  • Publication number: 20110230472
    Abstract: It is an object of the present invention to provide a compound or a pharmaceutically acceptable salt thereof which inhibits the activity of PI3K to regulate many biological processes including the growth, differentiation, survival, proliferation, migration, metabolism, and the like of cells and is therefore useful for the prophylaxis/therapy of diseases including inflammatory diseases, arteriosclerosis, vascular/circulatory diseases, cancer/tumors, immune system diseases, cell proliferative diseases, infectious diseases, and the like. The above problem was solved by providing a ring-fused azole compound shown in the present specification, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 25, 2009
    Publication date: September 22, 2011
    Applicant: Shionogi & Co., Ltd.
    Inventors: Yasunori Mitsuoka, Manami Masuda, Daisuke Taniyama
  • Publication number: 20110172217
    Abstract: The present invention provides compounds or a pharmaceutically acceptable salt thereof which inhibit the activity of PI3K to regulate many biological processes including the growth, differentiation, survival, proliferation, migration, metabolism, and the like of cells and are therefore useful for the prophylaxis/therapy of diseases including inflammatory diseases, arteriosclerosis, vascular/circulatory diseases, cancer/tumors, immune system diseases, cell proliferative diseases, infectious diseases, and the like. The above problem was solved by providing a ring-fused morpholine compound shown in the present specification, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 2, 2009
    Publication date: July 14, 2011
    Applicant: Shionogi & Co., Ltd.
    Inventors: Masahiko Fujioka, Susumu Mitsumori, Akira Kugimiya, Daisuke Taniyama
  • Publication number: 20110105457
    Abstract: The purpose of the present invention is to provide a compound or a pharmaceutically acceptable salt thereof which inhibits the activity of PI3K to regulate many biological processes including the growth, differentiation, survival, proliferation, migration, metabolism, and the like of cells and is therefore useful for the prevention/treatment of diseases including inflammatory diseases, arteriosclerosis, vascular/circulatory diseases, cancer/tumors, immune system diseases, cell proliferative diseases, infectious diseases, and the like. This was achieved by providing a substituted 2-amino-5,6-nitrogenated fused ring compound shown in the present specification, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 16, 2009
    Publication date: May 5, 2011
    Inventors: Daisuke Taniyama, Kazuya Kano, Kazuya Okamoto, Masahiko Fujioka, Yasunori Mitsuoka